Executive Summary
rep 2139 REP 2139-Mg 由加拿大Replicor公司牵头的一项核酸聚合物REP 2139-Ca联合PEG IFNα治疗HBV/HDV共感染患者的最新研究结果显示,82%的患者可获得丁肝的功能性治愈,45%的患者
REP 2139 is emerging as a significant therapeutic agent in the fight against chronic Hepatitis B Virus (HBV) and Hepatitis Delta Virus (HDV) infectionsPrevious clinical trials have demonstrated that treatment with the NAPREP 2139results in the rapid and effective clearance of HBsAg from the blood. This HBsAg This innovative nucleic acid polymer (NAP) has demonstrated remarkable antiviral activity in both pre-clinical and clinical studies, offering new hope for patients with these challenging liver diseasesREP 2139 is currently undergoing testing in human patients with chronic HBeAg+ HBVin a proof of concept clinical trial where patients were treated with REP The research surrounding REP 2139 highlights its ability to target the viruses through novel mechanisms, leading to improved patient outcomes作者:R Boulon·2020·被引用次数:67—Nucleic acid polymers (NAPs) such asREP 2139display promising antiviral activity against both. HBV and hepatitis Delta virus (HDV) in clinical
One of the key mechanisms of action for REP 2139 is its potent effect on Hepatitis B surface antigen (HBsAg)Significant reduction of HBsAg and HDVRNA by the Studies have shown that REP 2139 therapy by itself is accompanied by rapid declines in HBsAg in the blood and liver作者:R Boulon·2020·被引用次数:69—REP 2139 display promising antiviral activityagainst both HBV and hepatitis Delta virus (HDV) in clinical trials. This clearance of HBsAg is crucial because it is a primary indicator of active HBV infection and plays a role in immune toleranceSafety and efficacy of REP 2139 and pegylated interferon By reducing HBsAg, REP 2139 can help to restore the body's immune response against the virus, potentially leading to a functional cureIn pre-clinical and clinical studies in HBV infection,REP 2139 therapy by itself is accompanied by rapid declines in HBsAgin the blood and liver. Furthermore, REP 2139 has been shown to efficiently clear HBsAg from the blood, a critical step in managing chronic HBV乙肝在研新药REP 2139联合聚乙二醇干扰素α治疗HBV/HDV
Beyond its impact on HBsAg, REP 2139 also effectively targets HDV replication作者:C Stern·2025·被引用次数:7—REP 2139-Mg (REP), a nucleic acid polymer, blocks HBV subviral particle assembly and HDV replication. We hereby report results of REP treatment REP 2139-Mg, a specific formulation, has shown particular promiseStudy Details | NCT02233075 | REP 2139-Ca / Pegasys™ Clinical trials have indicated that REP treatment was safe and effective in patients with HDV and advanced chronic liver diseaseCharacterization of the antiviral effects of REP 2139 on In some cases, the addition of REP 2139-Mg to existing antiviral therapy led to clearance of HDV RNA after 17 weeks of REP 2139-Mg therapy with good tolerabilityPangenomic antiviral effect of REP 2139 in CRISPR/Cas9 This dual action against both HBV and HDV makes REP 2139 a valuable tool for treating co-infected individualsTherapeutic Safety and Efficacy of REP 2139 (REP 9AC') in The REP 2139 effectively blocks the assembly and release of HBV SVPs (subviral particles), further contributing to its antiviral efficacySafety and efficacy of REP 2139-Mg in patients with HDV-
The safety and efficacy profile of REP 2139 has been extensively evaluatedREP 2139 is currently undergoing testing in human patients with chronic HBeAg+ HBVin a proof of concept clinical trial where patients were treated with REP Open-label, phase 2 studies involving REP 2139 or REP 2165 combined with tenofovir disoproxil fumarate (TDF) have reported favorable resultsREP 2139 found to reduce HBsAg in Caucasians with HBV These studies underscore that REP treatment was safe and effective in patients with HDVREP 2139-Ca treatment was once weekly via 2 hour IV infusion. Researchers measured viremia, hepatitis B surface antigen (HBsAg), anti-HBs, HDV In one notable trial, REP 2139-Ca treatment was once weekly via 2 hour IV infusion, demonstrating a manageable administration schedule作者:R Boulon·2020·被引用次数:69—REP 2139 display promising antiviral activityagainst both HBV and hepatitis Delta virus (HDV) in clinical trials. The research consistently points towards REP 2139 being a well-tolerated option for patients作者:M Bazinet·2017·被引用次数:305—CombinedREP 2139and pegylated interferon alfa-2a therapy is safe, well tolerated, and establishes functional control of HBV and HDV co-infection.
REP 2139 is often studied as part of combination therapyReplicor announces activity of REP 2139-Mg in HBV/HDV For instance, REP 2139 in combination with pegylated interferon alfa-2a has been shown to be safe, well-tolerated, and capable of establishing functional control of HBV and HDV co-infectionReplicor announces activity of REP 2139-Mg in HBV/HDV In a study involving REP 2139-Ca and PEG IFNα, a significant percentage of patients achieved functional cure of HBV, highlighting the synergistic benefits of this combinationThis open label, randomized and controlled study will examine the safety and efficacy ofREP 2139-Mgand REP 2165-Mg therapy in patients with HBeAg negative This approach aims to maximize antiviral response and improve the chances of sustained virological responseREP 9AC (REP 2055) is a nucleic acid polymer (NAP) with entry and post-entry antiviral activity against duck hepatitis B virus (DHBV) infection.
The scientific community is actively investigating the broader applications of REP 2139作者:M Bazinet·2017·被引用次数:305—CombinedREP 2139and pegylated interferon alfa-2a therapy is safe, well tolerated, and establishes functional control of HBV and HDV co-infection. Researchers have explored its antiviral mechanisms and applications in HBV and HDV infection, providing updated reviews of available data作者:M Bazinet·2020·被引用次数:285—We performed an open-label, phase 2 study of the safety and efficacy of the NAPsREP 2139or REP 2165 combined with tenofovir disoproxil fumarate (TDF) and Studies have also examined the characterization of the antiviral effects of REP 2139 on the HBV and HDV viruses, revealing its broad spectrum of activity作者:M Bazinet·2020·被引用次数:285—We performed an open-label, phase 2 study of the safety and efficacy of the NAPsREP 2139or REP 2165 combined with tenofovir disoproxil fumarate (TDF) and Importantly, REP 2139 exerts an antiviral effect in all genotypes and serotypes tested in this study, including the vaccine escape mutant, suggesting its potential to overcome resistance mechanismsREP 2139 / Replicor
Different formulations of REP 2139, such as REP 9AC (REP 2055) and REP 2139-Ca, have been investigatedCONCLUSIONS:REP treatment was safe and effective in patients with HDV and advanced chronic liver disease. REP may induce sustained virological response of HDV REP 9AC (REP 2055), a nucleic acid polymer, exhibits both entry and post-entry antiviral activity against duck hepatitis B virus (DHBV) infectionREP 2139-鈣的聯合療法 REP 2139-Ca has been specifically studied for its ability to simultaneously reduce HBsAg and HDV RNA in patients with chronic HBV/HDV coinfectionPersistent Control of Hepatitis B Virus and Hepatitis Delta
The ongoing research and clinical trials, such as those investigating REP 2139-Mg and REP 2165-Mg therapy in patients with HBeAg negative HBV/HDV infections, continue to build a strong evidence base for this therapeutic class"REP 2139-Ca is able to simultaneously reduce HBsAg and HDV RNA in patients with chronic HBV/HDV coinfection," the researchers concluded. " The data suggests that REP 2139 is not just a surface antigen inhibitor but a compound that can lead to sustained control of these viral infectionsThe nucleic acid polymerREP 2139inhibits assembly/secretion of hepatitis B virus (HBV) subviral particles. Previously, REP 2139-Ca and As research progresses, REP 2139 holds significant promise for transforming the treatment landscape for individuals living with HBV and HDV乙肝在研新药REP 2139联合聚乙二醇干扰素α治疗HBV/HDV
Related Articles
Frequently Asked Questions
Here are the most common questions about rep 2139.
Leave a Comment
Share your thoughts, feedback, or additional insights on this topic.
